Key message

• Centre for Shared Decision Making “Samvalgssenteret” asked the Norwegian Institute of Public Health to find and summarize key findings from systematic reviews about the effectiveness of palliative care and folfirinox, gemcitabine and gemcitabine + nabpaclitaxel for patients with pancreatic cancer.
  
  We identified one systematic reviews, and this systematic review included four studies with relevance for three of our six comparisons. Briefly, we found that:

• There may be little or no difference in survival with gemcitabine compared to palliative care. We did not identify studies measuring quality of life, symptoms and side effects.
• There may be better survival, increased relief of symptoms and fewer who experience reduced quality of life with folfirinox compared to gemcitabine, but the number of side effect may increase.
• Survival and symptom relief may improve with gemcitabine + nab‐paclitaxel compared to gemcitabine alone, but may also lead to more side effect. We did not find research assessing differences in quality of life.
• We don’t know if there are differences in effectiveness between palliative care and folfirinox because we did not find relevant research.
• We don’t know if there are differences in effectiveness between palliative care compared to gemcitabine + nabpaclitaxel because we did not find relevant research.
• We don’t know if there are differences in effectiveness between folfirinox and gemcitabine + nab‐paclitaxel because we did not find relevant research.